Intraperitoneal hyperthermic chemotherapy in ovarian cancer

• Published in: International journal of gynecological cancer Vol. 15; no. 2; pp. 233 - 239
• Main Authors: Gori, J., Castaño, R., Toziano, M., HÄBICH, D., Staringer, J., De Quirós, D. G.B., Felci, N.
• Format: Journal Article
• Language: English
• Published: Oxford BMJ Publishing Group LTD 01.02.2005
• Subjects: Cancer therapies; Chemotherapy; Ovarian cancer; Surgery
• ISSN: 1048-891X; 1525-1438
• DOI: 10.1136/ijgc-00009577-200503000-00008

We investigated the effect of intraperitoneal hyperthermic perfusion chemotherapy as consolidation therapy in stage IIIB–IIIC ovarian cancer, following cytoreductive surgery and systemic chemotherapy (cisplatin–cyclophosphamide—six cycles). Disease-free survival, overall survival, and side effects were compared with a control group of patients who refused a second-look surgery and intraperitoneal chemotherapy. In a multicenter prospective trial, 29 patients with complete or optimal cytoreductive surgery and systemic treatment were included in the consolidation group and received intraperitoneal hyperthermic perfusion chemotherapy. Patients were recruited between January 1991 and December 1997. The intraperitoneal hyperthermic perfusion was performed with open-abdomen technique, using physiologic solution containing cisplatin 100 mg/m 2 , for 60 min in hyperthermic phase (41–43°C). Intraperitoneal hyperthermic perfusion chemotherapy was locally and systemically well tolerated. The consolidation therapy group showed a better 5-year survival rate and lower recurrent disease rate, but differences were not statistically significant. Our results suggest that intraperitoneal hyperthermic perfusion chemotherapy is a feasible, well-tolerated, and promising alternative as consolidation therapy in ovarian cancer.